A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals. Here we present the results from a first-in-human trial of the candidate simian adenovirus vectored vaccine ChAdOx1 Chik...

Full description

Bibliographic Details
Main Authors:	Folegatti, P, Harrison, K, Preciado-Llanes, L, Ramos Lopez, F, Bittaye, M, Kim, Y, Flaxman, A, Bellamy, D, Makinson, R, Sheridan, J, Tilley, M, Tran, N, Jenkin, D, Poulton, I, Lawrie, A, Roberts, R, Berrie, E, Hill, A, Ewer, K, Reyes-Sandoval, A
Format:	Journal article
Language:	English
Published:	Springer Nature 2021

Similar Items

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
by: Pedro M. Folegatti, et al.
Published: (2021-07-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
by: Folegatti, P, et al.
Published: (2019)

The “Chik Sign” in Neonatal Chikungunya
by: Jayasree Chandramathi, et al.
Published: (2020-06-01)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
by: Sharpe, HR, et al.
Published: (2022)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
by: Pedro M. Folegatti, et al.
Published: (2019-05-01)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
by: Folegatti, PM, et al.
Published: (2019)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
by: Hannah R. Sharpe, et al.
Published: (2022-03-01)

“Chik sign” in chikungunya: three cases with dermoscopic findings
by: Sambasiviah Chidambara Murthy, et al.
Published: (2022-01-01)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
by: Bosaeed, M, et al.
Published: (2021)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
by: Barrett, J, et al.
Published: (2020)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
by: Moreira Folegatti, P
Published: (2021)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
by: Ogbe, A, et al.
Published: (2022)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
by: Folegatti, P, et al.
Published: (2021)

Chik Sign: A Clinical Clue to Chikungunya Infection- A Case Series
by: Geo Danny, et al.
Published: (2024-06-01)

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
by: Folegatti, PM, et al.
Published: (2020)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
by: Folegatti, PM, et al.
Published: (2020)

Seroprevalence of Chikungunya (CHIK) Infection during Non Epidemic Periods in Chennai, Southern India
by: Kaliyamoorthy Kayalvili, et al.
Published: (2021-09-01)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
by: Alharbi, N, et al.
Published: (2017)

Chik Sign
by: Preeti Keyur Sheth, et al.
Published: (2022-01-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
by: Zhang, C, et al.
Published: (2023)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
by: Marchevsky, NG, et al.
Published: (2022)

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
by: Sklar, MJ, et al.
Published: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
by: Cheng Zhang, et al.
Published: (2023-06-01)

“Chik” from the womb!
by: Samipa Samir Mukherjee, et al.
Published: (2017-01-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
by: Ane Ogbe, et al.
Published: (2022-04-01)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
by: Charlotte Davis, et al.
Published: (2024-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
by: Adam Berg, et al.
Published: (2021-10-01)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
by: Voysey, M, et al.
Published: (2023)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
by: Pedro M. Folegatti, et al.
Published: (2021-03-01)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
by: Natalie Gabrielle Marchevsky, et al.
Published: (2022-07-01)

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
by: Folegatti, PM, et al.
Published: (2020)

Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against Chikungunya virus
by: López-Camacho, C, et al.
Published: (2019)

Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
by: Shweta Saraswat, et al.
Published: (2016-07-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
by: Flaxman, A, et al.
Published: (2021)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
by: Ramasamy, MN, et al.
Published: (2020)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
by: Frater, J, et al.
Published: (2021)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
by: Hermosilla, E, et al.
Published: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
by: Eduardo Hermosilla, et al.
Published: (2022-03-01)

Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced protection from malaria
by: Noe, A, et al.
Published: (2022)

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
by: Javier García-Pérez, et al.
Published: (2022-08-01)